| advanced breast cancer (metastatic) | cisplatin | not classified | versus No demonstrated result for efficacy | 13 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | |
| Trial | Treatments | Patients | Method |
|---|
| Berruti A, 2002 | cisplatin + epirubicin (n=-9) vs. lonidamine + epirubicin (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Berruti B, 2002 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Cocconi, 1999 | The same single agents (C, M, F, cisplatin, etoposide, and doxorubicin) were administered in both experimental arms, but following a different policy. (n=-9) vs. cyclophosphamide, methotrexate, and 5-fluorouracil (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Costanza, 1999 | carboplatin followed by CAF (n=-9) vs. immediate chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil (CAF) (n=-9) | women with measurable metastatic breast cancer, previously untreated with chemotherapy for their metastatic disease | Sample size: -9/-9 Primary endpoint: FU duration: | | Creagan ET, 1984 | four cycles of cyclophosphamide, Adriamycin (Adria Laboratories, Inc, Columbus, Ohio), cisplatin (CAP) followed by maintenance with cyclophosphamide, 5-fluorouracil, prednisone (CFP) (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Nielsen, 2000 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Cocconi, 1991 | cisplatin (P) and etoposide (E) (n=-9) vs. standard cyclophosphamide, methotrexate, and fluorouracil (CMF) (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Cocconi G, 1996 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Eisen, 1998 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Fountzilas, 2002 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Icli, 2002 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Kolaric, 1985 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Kolaric, 1989 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
|
